Corrigendum: Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis.

Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu

Abstract readPublished Erratum

In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Association between log odds of positive lymph nodes and survival in surgically treated cervical cancer patients: a SEER database-based cohort study.World journal of surgical oncology · 2026
Article
The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway.Cancer cell international · 2023
Article

4 · The record

Corrections and comments

Erratum for
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis.2022

5 · Who and what money

Authors and funding

7 authors.

Jianying YiDepartment of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.

Zhili LiuDepartment of Clinical Laboratory, The Third Central Hospital, Tianjin, China.

Lu WangDepartment of Gynecology and Obstetrics, Traditional Chinese Medicine Hospital of Xiaoyi City, Xiaoyi, China.

Xingxin ZhangDepartment of Clinical Laboratory, People's Hospital of Xiaoyi City, Xiaoyi, China.

Lili PiDepartment of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.

Chunlei ZhouDepartment of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.

Hong MuDepartment of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.857375.].

Indexed as

cancer-specific survivalcervical cancerlymph node metastasisnomogramoverall survival

Identifiers

PMID35574297

DOI10.3389/fonc.2022.916310

PMCPMC9097262

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.